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Abstract
Diabetes Mellitus (DM) is caused by a lack of insulin production (Type 1) or the body’s cells’
inability to properly receive it, also known as insulin resistance (Type 2), resulting in greatly ele-
vated levels of blood glucose. Vanadium(IV) and vanadium(V) ions are believed to enhance insulin
activity by inhibition of protein tyrosine phosphatase 1B (PTP1B). PTP1B is normally responsible
for downregulating the insulin signaling, but in DM type 2, PTP1B activity is overexpressed lead-
ing to the insulin signaling blocking. The most promising V(IV) compounds are designed for oral
delivery: they are absorbed into the gut and delivered into the bloodstream where they are bound
by the iron transporting protein serum transferrin (sTf). STf delivers the compound into cells via
endocytosis, where vanadium can bind PTP1B. A limitation of these compounds is their poor sta-
bility at the stomach acidic conditions in which they undergo a significant amount of dissociation,
resulting in a very inefficient gut absorption. This study explores the use of a chemical transferrin
mimetic (cTfm) ligand to create V(IV) and V(V) compounds featuring excellent acidic pH stabil-
ity for improved gut absorption. The cTfm-V(IV,V) compounds are expected to be labile in the pH
of the bloodstream and thus the vanadium species can be quickly ligand exchanged with sTF. The
cTfm ligand N,N’-di(o-hydroxybenzyl)ethylenediamine-N,N’-diacetic acid (HBED) was used to
synthesize VO(IV)HBED and VO(V)HBED which demonstrated great aqueous stability in the 1-4
pH range. The role of citrate as a vehicle for delivering vanadium to sTf to regulate the transport
of vanadium is also examined.
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ABSTRACT 
Diabetes Mellitus (DM) is caused by a lack of insulin production (Type 1) or the body’s 
cells’ inability to properly receive it, also known as insulin resistance (Type 2), resulting in 
greatly elevated levels of blood glucose. Vanadium(IV) and vanadium(V) ions are believed to 
enhance insulin activity by inhibition of protein tyrosine phosphatase 1B (PTP1B). PTP1B is 
normally responsible for downregulating the insulin signaling, but in DM type 2, PTP1B 
activity is overexpressed leading to the insulin signaling blocking. The most promising V(IV) 
compounds are designed for oral delivery: they are absorbed into the gut and delivered into the 
bloodstream where they are bound by the iron transporting protein serum transferrin (sTf). STf 
delivers the compound into cells via endocytosis, where vanadium can bind PTP1B. A 
limitation of these compounds is their poor stability at the stomach acidic conditions in which 
they undergo a significant amount of dissociation, resulting in a very inefficient gut absorption. 
This study explores the use of a chemical transferrin mimetic (cTfm) ligand to create V(IV) 
and V(V) compounds featuring excellent acidic pH stability for improved gut absorption. The 
cTfm-V(IV,V) compounds are expected to be labile in the pH of the bloodstream and thus the 
vanadium species can be quickly ligand exchanged with sTF. The cTfm ligand N,N'-di(o-
hydroxybenzyl)ethylenediamine-N,N'-diacetic acid (HBED) was used to synthesize 
VO(IV)HBED and VO(V)HBED which demonstrated great aqueous stability in the 1-4 pH 
range. The role of citrate as a vehicle for delivering vanadium to sTf to regulate the transport 
of vanadium is also examined. 
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